ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0740

Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT

Betty Hsiao1, Julie Downs2, Mandy Lanyon2, William Nowell3, SHILPA VENKATACHALAM4, Carole Wiedmeyer5, Jeffrey Curtis6, Susan Blalock7, Leslie Harrold8 and Liana Fraenkel9, 1Yale-New Haven Medical Center, New Haven, CT, 2Carnegie Mellon, Pittsburgh, PA, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Global Healthy Living Foundation, New York, NY, 5Global Healthy Living Foundation, Nyack, NY, 6Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 7Chapel Hill, Chapel Hill, NC, 8Corrona, LLC, Northborough, MA, 9Berkshire Medical Center, Lenox, MA

Meeting: ACR Convergence 2021

Keywords: Decision Making, Patient preference, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Fewer than 50% of patients with rheumatoid arthritis (RA) are treated using a TTT strategy. The purpose of this study was to better understand rheumatologists’ and patients’ decision making regarding TTT using the Mental Models Approach to Risk Communication (MMARC). The MMARC provides a rigorous framework to develop interventions that address critical discrepancies between the mental models held by different populations, in this context, rheumatologists and patients.

Methods: We conducted semi-structured interviews with 14 rheumatologists and 30 patients to elicit respondents’ views regarding treatment decisions in RA, with a focus on TTT. Interviews were transcribed and coded independently by two researchers. Final agreement between coders was high (kappa > 95%). We report the prevalence of each concept mentioned using the corresponding code. Because some ideas may not be expressed, these proportions represent a lower bound of their prevalence in people’s mental models.

Results: Table 1 presents all factors raised in the interviews. Based on the codes assigned to each set of interviews, we created one model representing how rheumatologists conceptualize TTT (Figure 1) and another representing how patients conceptualize their treatment (Figure 2). Border thickness represent the frequency with which concepts were raised. Empty shapes highlight discrepancies between the rheumatologist and patient models. Several physicians stated that treatment decisions should be made based on overall trajectory of disease rather than at the point-of-care. They also described the importance of adherence and response to previous DMARDs on their decision making. Physicians recognized system barriers at the patient level (e.g., inadequate transportation), practice level, and insurance. Physicians also described how their own preferences and pharmaceutical company influences might affect their treatment decisions.

Notably absent from the patients’ mental model is the cornerstone of TTT, i.e., disease activity measurement using validated instruments. Patients’ anticipation of future experience on new medications. They described the necessity of feeling adequately informed, including from sources outside of their rheumatologist, in order to make treatment changes. Several discussed the burden of making treatment decisions. The uncertainty regarding whether one will benefit from a new DMARD and the risk of new side effects was frequently mentioned as an adverse aspect of changing medications. Concerns of the influence of pharmaceutical companies on rheumatologists’ recommendations were also raised.

Conclusion: The TTT model of care is specific and prescriptive: measure disease activity and adjust treatment to achieve or maintain a predefined target using shared decision making. However, rheumatologists’ and patients’ mental models of treatment decision making in RA are much more complex and explain the low rates of TTT implementation. We found several discrepancies primarily related to differences in how patients and physicians value trade-offs that can serve as specific targets to improve patient-physician communication and ultimately inform interventions to improve uptake of TTT.

Table 1. Concepts Raised by Physicians and Patients

Physician Mental Model

Patient Mental Model


Disclosures: B. Hsiao, None; J. Downs, None; M. Lanyon, None; W. Nowell, Global Healthy Living Foundation, 3, AbbVie, 5, Amgen, 5, Eli Lilly, 5; S. VENKATACHALAM, None; C. Wiedmeyer, None; J. Curtis, AbbVie, 2, Amgen, 2, 5, Bristol-Myers Squibb, 2, Janssen, 2, Eli Lilly, 2, Myriad, 2, Pfizer Inc, 2, 5, Roche/Genentech, 2, UCB, 2, CorEvitas, 2, 5, Crescendo Bio, 5; S. Blalock, None; L. Harrold, Bristol-Myers Squibb, 2, Roche, 2, AbbVie, 2, Pfizer, 5; L. Fraenkel, None.

To cite this abstract in AMA style:

Hsiao B, Downs J, Lanyon M, Nowell W, VENKATACHALAM S, Wiedmeyer C, Curtis J, Blalock S, Harrold L, Fraenkel L. Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/rheumatologists-and-patients-mental-models-for-treatment-of-ra-explain-low-rates-of-ttt/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatologists-and-patients-mental-models-for-treatment-of-ra-explain-low-rates-of-ttt/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences